دورية أكاديمية
Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
العنوان: | Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. |
---|---|
المؤلفون: | Tripolt S; Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria., Neubauer HA; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria., Knab VM; Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria., Elmer DP; Department of Biosciences, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, Austria., Aberger F; Department of Biosciences, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, Austria., Moriggl R; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria., Fux DA; Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria. Electronic address: sabrina_tripolt@gmx.net. |
المصدر: | Neoplasia (New York, N.Y.) [Neoplasia] 2021 Feb; Vol. 23 (2), pp. 270-279. Date of Electronic Publication: 2021 Jan 16. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2014- : [Amsterdam] : Elsevier Original Publication: New York, NY : Stockton Press, c1999- |
مواضيع طبية MeSH: | Analgesics, Opioid/*pharmacology , Breast Neoplasms/*metabolism , Breast Neoplasms/*pathology , Receptors, Opioid, delta/*metabolism , STAT3 Transcription Factor/*metabolism, Animals ; Biomarkers ; Breast Neoplasms/etiology ; Cell Line, Tumor ; Disease Models, Animal ; Disease Susceptibility ; Female ; Gene Expression ; Humans ; Immunohistochemistry ; Mice ; Mice, Transgenic ; Neoplasm Metastasis ; Oncogene Proteins/metabolism ; Receptors, Opioid, delta/agonists ; Receptors, Opioid, delta/genetics |
مستخلص: | The opioid crisis of pain medication bears risks from addiction to cancer progression, but little experimental evidence exists. Expression of δ-opioid receptors (DORs) correlates with poor prognosis for breast cancer patients, but mechanistic insights into oncogenic signaling mechanisms of opioid-triggered cancer progression are lacking. We show that orthotopic transplant models using human or murine breast cancer cells displayed enhanced metastasis upon opioid-induced DOR stimulation. Interestingly, opioid-exposed breast cancer cells showed enhanced migration and strong STAT3 activation, which was efficiently blocked by a DOR-antagonist. Furthermore, opioid treatment resulted in down-regulation of E-Cadherin and increased expression of epithelial-mesenchymal transition markers. Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo. We conclude on a novel mechanism whereby opioid-triggered breast cancer metastasis occurs via oncogenic JAK1/2-STAT3 signaling to promote epithelial-mesenchymal transition. These findings emphasize the importance of selective and restricted opioid use, as well as the need for safer pain medication that does not activate these oncogenic pathways. (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.) |
References: | FASEB J. 2010 Jun;24(6):1838-51. (PMID: 20097873) Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191. (PMID: 30052758) Anesth Analg. 2008 Jul;107(1):325-32. (PMID: 18635504) Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5587-91. (PMID: 1905813) Mol Cancer Res. 2011 Dec;9(12):1658-67. (PMID: 21976712) BMB Rep. 2016 Nov;49(11):623-628. (PMID: 27697106) J Recept Signal Transduct Res. 2015;35(6):600-4. (PMID: 26096166) Neoplasia. 2004 Jan-Feb;6(1):1-6. (PMID: 15068665) PLoS One. 2012;7(8):e42616. (PMID: 22900034) J Pharmacol Exp Ther. 2004 May;309(2):776-85. (PMID: 14742744) Oncogene. 2016 Feb 25;35(8):1049-57. (PMID: 25961936) J Clin Anesth. 2015 Dec;27(8):672-9. (PMID: 26371714) Clin Diagn Lab Immunol. 2000 Sep;7(5):719-23. (PMID: 10973443) J Immunol. 1995 May 15;154(10):5049-60. (PMID: 7730611) J Biol Chem. 2008 May 23;283(21):14665-73. (PMID: 18353781) PLoS One. 2013;8(1):e55145. (PMID: 23372829) Neuropharmacology. 2009;56 Suppl 1:205-12. (PMID: 18718480) Cancer. 2013 Dec 1;119(23):4103-10. (PMID: 24104703) Anesthesiology. 2011 Dec;115(6):1363-81. (PMID: 22020140) Circ J. 2012;76(1):204-12. (PMID: 22033345) JAKSTAT. 2014 Jan 1;3(1):e28975. (PMID: 24843831) Open Biol. 2012 May;2(5):120076. (PMID: 22724071) Anesthesiology. 2006 Oct;105(4):660-4. (PMID: 17006061) Differentiation. 2006 Apr;74(4):174-85. (PMID: 16683988) Oncol Rep. 2016 Nov;36(5):2579-2586. (PMID: 27665747) Drug Alcohol Depend. 2012 Aug 1;124(3):223-8. (PMID: 22356890) Melanoma Res. 2000 Apr;10(2):165-9. (PMID: 10803717) Life Sci. 1995;56(2):PL45-50. (PMID: 7823756) Br J Cancer. 2007 Dec 3;97(11):1523-31. (PMID: 17971769) Methods Mol Biol. 2007;397:67-78. (PMID: 18025714) J Biol Chem. 2005 Mar 18;280(11):10710-5. (PMID: 15640156) J Vis Exp. 2016 Aug 14;(114):. (PMID: 27584043) Eur J Pharmacol. 1992 Mar 24;213(2):219-25. (PMID: 1355735) Cell Signal. 2002 May;14(5):381-95. (PMID: 11882383) J Pharmacol Exp Ther. 1995 Jun;273(3):1105-13. (PMID: 7791081) Br J Anaesth. 2014 Oct 10;113(Suppl 1):i109-i116. (PMID: 25303989) Oncogene. 2004 Jan 8;23(1):168-78. (PMID: 14712222) Nat Commun. 2016 Jul 13;7:12258. (PMID: 27406745) Gen Physiol Biophys. 2018 May;37(3):299-307. (PMID: 29589835) Sci Signal. 2014 Sep 30;7(345):ra92. (PMID: 25270258) Oncoimmunology. 2012 Oct 1;1(7):1027-1037. (PMID: 23170251) Leukemia. 2014 Mar;28(3):629-41. (PMID: 24263804) Biochem Biophys Res Commun. 2003 Apr 11;303(3):920-5. (PMID: 12670499) J Neuroimmunol. 1988 May;18(2):125-38. (PMID: 2833533) Chin Med J (Engl). 2004 Aug;117(8):1135-42. (PMID: 15361284) Neuroimmunomodulation. 2004;11(4):255-60. (PMID: 15249732) J Pharmacol Exp Ther. 1998 May;285(2):820-7. (PMID: 9580632) DNA Cell Biol. 2000 Apr;19(4):195-204. (PMID: 10798443) Science. 2009 Jun 26;324(5935):1713-6. (PMID: 19556508) Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834) Br J Pharmacol. 2015 Jan;172(2):501-14. (PMID: 24628261) |
معلومات مُعتمدة: | I 4157 Austria FWF_ Austrian Science Fund FWF |
فهرسة مساهمة: | Keywords: Breast cancer; EMT; Metastasis; Opioid; STAT3 |
المشرفين على المادة: | 0 (Analgesics, Opioid) 0 (Biomarkers) 0 (Oncogene Proteins) 0 (Receptors, Opioid, delta) 0 (STAT3 Transcription Factor) |
تواريخ الأحداث: | Date Created: 20210119 Date Completed: 20211012 Latest Revision: 20230517 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC7815495 |
DOI: | 10.1016/j.neo.2020.12.011 |
PMID: | 33465556 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1476-5586 |
---|---|
DOI: | 10.1016/j.neo.2020.12.011 |